Literature DB >> 20163446

Posterior glucose hypometabolism in Lafora disease: early and late FDG-PET assessment.

Melanie Jennesson1, Mathieu Milh, Nathalie Villeneuve, Eric Guedj, Pierre-Yves Marie, Jean-Pierre Vignal, Emmanuel Raffo, Hervé Vespignani, Josette Mancini, Louis Maillard.   

Abstract

Establishing an early diagnosis of Lafora disease (LD) is often challenging. We describe two cases of LD presenting as myoclonus and tonic-clonic seizures, initially suggesting idiopathic generalized epilepsy. The subsequent course of the disease was characterized by drug-resistant myoclonic epilepsy, cognitive decline, and visual symptoms, which oriented the diagnosis toward progressive myoclonic epilepsy and, more specifically, LD. Early in the evolution in the first case, and before histopathologic and genetic confirmation of LD in both cases, [18]Fluorodeoxyglucose positron emission tomography (FDG-PET) revealed posterior hypometabolism, consistent with the well-known posterior impairment in this disease. This suggests that FDG-PET could help to differentiate LD in early stages from other progressive myoclonic epilepsies, but confirmation is required by a longitudinal study of FDG-PET in progressive myoclonic epilepsy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20163446     DOI: 10.1111/j.1528-1167.2009.02498.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  7 in total

Review 1.  Lafora disease: epidemiology, pathophysiology and management.

Authors:  Thomas S Monaghan; Norman Delanty
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

Review 2.  [Lafora disease: a review of the literature].

Authors:  L Desdentado; R Espert; P Sanz; J Tirapu-Ustarroz
Journal:  Rev Neurol       Date:  2019-01-16       Impact factor: 0.870

3.  FDG-PET assessment and metabolic patterns in Lafora disease.

Authors:  Lorenzo Muccioli; Andrea Farolfi; Federica Pondrelli; Giuseppe d'Orsi; Roberto Michelucci; Elena Freri; Laura Canafoglia; Laura Licchetta; Francesco Toni; Rachele Bonfiglioli; Simona Civollani; Cinzia Pettinato; Elisa Maietti; Giorgio Marotta; Stefano Fanti; Paolo Tinuper; Francesca Bisulli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-19       Impact factor: 9.236

Review 4.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

Review 5.  Lafora disease.

Authors:  Julie Turnbull; Erica Tiberia; Pasquale Striano; Pierre Genton; Stirling Carpenter; Cameron A Ackerley; Berge A Minassian
Journal:  Epileptic Disord       Date:  2016-09-01       Impact factor: 1.819

6.  Frontal Hypoperfusion and the Effectiveness of Perampanel in Long-Lived Patient with Lafora Disease.

Authors:  Koji Obara; Erika Abe; Itaru Toyoshima
Journal:  Case Rep Neurol       Date:  2021-03-22

7.  Structural and Functional Brain Abnormalities in Mouse Models of Lafora Disease.

Authors:  Daniel F Burgos; Lorena Cussó; Gentzane Sánchez-Elexpuru; Daniel Calle; Max Bautista Perpinyà; Manuel Desco; José M Serratosa; Marina P Sánchez
Journal:  Int J Mol Sci       Date:  2020-10-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.